- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Tykerb, Tyverb
Synonyms :
Lapatinib
Class :
Antineoplastics, Anti-HER2; Tyrosine Kinase Inhibitor; EGFR Inhibitor
Dosage Forms & Strengths:
Tablet
250 mg
Metastatic Breast Cancer i.e., HER2-overexpressing
1250 mg per day should be given orally from 1st to 21st day along with capecitabine on 1st to 14th day, repeatedly in a 21-day cycle
HER2-positive advanced breast cancer:
1500 mg orally each day in combination with 2.5 mg lapatinib orally each day
Dose modifications:
Diarrhea
In case of Grade 3 diarrhea interrupt the dosing
Other toxicities
In case of Grade 2 or more toxicity interrupt the dosing
It is not safe to administer lapatinib in the pediatric population
Refer to the adult dosing
lapatinib increases the effect of flibanserin by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lefamulin increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lomitapide increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib increases the effect of lonafarnib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
the level of pimozide is increased by lapatinib by decreasing the metabolism
may increase the QTc prolonging effect of QT-prolonging agents
abametapir increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
with the help of the P-glycoprotein MDR1 efflux transporter, lapatinib increases the effect of afatinib
alpelisib and lapatinib will increase the effect of each other when used simultaneously
both lapatinib and amiodarone increase the QTc interval
both lapatinib and amisulpride increase the QTc level
apalutamide decreases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
both lapatinib and arsenic trioxide increase the QTc interval
both lapatinib and artemether increase the QTc interval
avapritinib increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
axitinib increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib increases the effect of bosutinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
carbamazepine decreases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
both lapatinib and ceritinib increase the QTc interval
chloramphenicol increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
clarithromycin increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
cobicistat increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib increases the effect of cobimetinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
colchicine and lapatinib increase the effect of each other when used simultaneously
darolutamide and lapatinib increase the effect of each other when used simultaneously
both lapatinib and desflurane increase the QTc interval
lapatinib increases the effect of dihydroergotamine by altering the intestinal or hepatic CYP3A4 enzyme metabolism
dihydroergotamine intranasal increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
both lapatinib and disopyramide increase the QTc interval
lapatinib increases the effect of dronedarone by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib increases the level of effectiveness of edoxaban through P-glycoprotein MDR1 efflux transporter
lapatinib increases the effect of eliglustat by altering the intestinal or hepatic CYP3A4 enzyme metabolism
both lapatinib and encorafenib increase the QTc interval
lapatinib increases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
enzalutamide decreases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
erdafitinib increases the effect of lapatinib with the help of P-glycoprotein MDR1 efflux transporter
lapatinib increases the effect of ergotamine by altering the intestinal or hepatic CYP3A4 enzyme metabolism
both lapatinib and eribulin increase the QTc interval
erythromycin base increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
erythromycin ethyl succinate increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
erythromycin lactobionate increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
erythromycin stearate increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
everolimus increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
fentanyl increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
fentanyl intranasal increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
fentanyl transdermal increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
fentanyl transmucosal increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
both lapatinib and fexinidazole increase the QTc interval
both lapatinib and gilteritinib increase the QTc interval
both lapatinib and glasdegib increase the QTc interval
both lapatinib and hydroxychloroquine sulfate increase the QTc interval
both lapatinib and ibutilide increase the QTc interval
idelalisib increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
both lapatinib and indapamide increase the QTc interval
lapatinib increases the effect of infigratinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
both lapatinib and inotuzumab increase the QTc interval
both lapatinib and isoflurane increase the QTc interval
itraconazole increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
ivabradine increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
both lapatinib and ivosidenib increase the QTc interval
ketoconazole increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lasmiditan, when taken with lapatinib, simultaneously increases the effect of one another
lemborexant increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
levoketoconazole increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lopinavir increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lovastatin increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lurbinectedin increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
both lapatinib and macimorelin increase the QTc interval
midazolam intranasal increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib increases the effect of mobocertinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
naloxegol increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
nefazodone increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
neratinib increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib increases the effect of olaparib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
both lapatinib and ondansetron increase the QTc interval
lapatinib and ozanimod increase the toxicity of one another when used simultaneously
lapatinib increases the effect of pacritinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib and palifermin increase the toxicity of one another when used simultaneously
both lapatinib and panobinostat increase the QTc interval
lapatinib increases the effect of pazopanib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib increases the effect of ranolazine by altering the intestinal or hepatic CYP3A4 enzyme metabolism
